Global rapid microbiology testing market is likely to witness the highest CAGR of 9.24% from 2023-2031. The market revenue was US$ 4.3 billion in 2022 and is estimated to record a revenue of US$ 8.8 billion by 2031, driven by increasing demand for faster and more accurate testing methods in various industries.
Request Sample Copy of Research Report @ https://www.astuteanalytica.com/request-sample/rapid-microbiology-testing-market
Rapid microbiology testing is an automated solution for the rapid detection, response, and resolution of microbial contamination in samples involved in the manufacturing process. Microbiologist in clinical laboratories in the past has recognized the need for rapid results from microbiological testing.
The rapid identification methodology in the clinical microbiology lab has become a regular procedure. These techniques include automated modifications of the conventional biochemical and phenotypic microbial identification tests and alternative quick tests based on nucleic acids or Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI/TOF). Rapid microbiological techniques have changed clinical microbiology and elevated patient care due to their usefulness.
Infectious diseases like tuberculosis, HIV, COVID-19, pneumonia, and malaria are now more common. As a result, there are now more awareness campaigns for these diseases to promote early detection and preventive healthcare. The need for rapid microbiological procedures has grown as the incidence of these diseases has increased. For instance, the World Health Organization (WHO) reports that as of the beginning of 2023, more than 76 million people had received COVID-19 diagnoses worldwide, and more than 6.8 million of those people passed away from the illness. However, since its peak, the number of new cases has significantly decreased. These methods allow for quick and precise microbial screening, identification, and testing against diseases, which is likely to propel market expansion.
North America to Lead the Global Rapid Microbiology Testing Industry, Recording a Share of 38%
The high prevalence of microbial infections in the area and the sophisticated healthcare infrastructure that facilitates rapid microbiology testing are two factors that contribute to this market domination.
With millions of cases recorded each year, infectious diseases in North America have a heavy toll. With approximately 4.4 million notifiable infectious disease cases recorded in the United States in 2021 alone, infectious diseases continue to pose a serious threat to public health. Similar to the United States, approximately 225,000 instances of notifiable infectious illnesses were reported in Canada in 2021, making them a serious public health concern.
Contrarily, the Asia Pacific will experience the fastest growth rate due to rising healthcare costs and an increase in regional measures to encourage the adoption of modern rapid microbiology testing methods.
Product Segment Insights
Due to the increased demand for quick and precise microbe detection and identification, the instrument segment is likely to dominate the market and earn over 54% of the revenue share. This is especially significant in fields where prompt decision-making is essential, such as clinical, food and beverage, and environmental testing laboratories.
Method Segment Insights
By 2031, growth-based rapid microbiology testing is likely to dominate the market and hold over a 38% revenue share due to its low cost, simplicity of use, and capacity to identify a wide variety of microorganisms. The food and beverage sector has adopted these techniques to assure food safety, while the pharmaceutical industry is the major end-user of growth-based rapid microbiology testing methods. In clinical diagnostics, these techniques are utilized for the early diagnosis and treatment of infections.
Application Segment Insights
The clinical diagnosis segment is likely to dominate the global microbiological testing market. Rapid microbiology testing techniques are used in clinical diagnosis to find and classify infectious bacteria in clinical materials such as blood, urine, and sputum. The demand for rapid microbiology testing techniques in clinical settings is due to the rising prevalence of infectious disorders like COVID-19. Further promoting the use of these techniques in clinical diagnosis across the rapid microbiology testing market, technological developments in rapid microbiology testing methods, such as the use of molecular diagnostics and automated systems, have increased the efficiency and accuracy of testing.
The global market for pharmaceutical and biotech microbiological testing was estimated to be worth $920.85 million in 2022 and is likely to grow to $1,995 million by 2031, according to a report by Astute Analytica. According to the study, factors including rising drug approval rates and growing demand for quality control testing are fueling this market’s expansion.
The rapid microbiology testing market is moderately competitive. The businesses have seen the big players’ methods for gaining a competitive edge, including new product launches, mergers and acquisitions, partnerships, joint ventures, and strategies for partnerships. The businesses are also introducing sophisticated, time-saving automated microbiological technologies with high throughput.
Some of the strategies adopted by key players include:
In Sept 2022, Microgenetics developed a Rapid Microbial Method with a six-hour turnaround time. This crucial stage is costing many businesses time and resources because compendial methods of microbial contamination tests have a turnaround time of 14 days, and even faster technologies take about 4 days.
In Aug 2022, Together, BD and Accelerate Diagnostics are fighting antibiotic resistance. Through a global commercial partnership, BD will make available Accelerate’s rapid testing solution for antibiotic resistance and susceptibility, which provides results in hours as opposed to one to two days, as is the case with some conventional laboratory techniques.
In March 2021, Soleris® a next-generation, rapid microbiological testing technology from NEOGEN. A quick, automated microbial testing platform for product safety and quality, Soleris Next Generation (NG) provides rapid and accurate identification of microorganisms in food, nutraceutical, and cosmetic matrices.
In Feb 2021, Becton, Dickinson, and Company and Scanwell Health established a partnership to develop an at-home COVID-19 fast test using a BD antigen test and the Scanwell Health mobile app. BD created a lateral flow antigen test as part of the cooperation, and it will pair with the Scanwell Health mobile app. The software is likely to provide detailed instructions on how to take a nasal swab sample, transfer it, and utilize the camera on the phone to examine and interpret the results.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.astuteanalytica.com/industry-report/rapid-microbiology-testing-market
- Abbott Laboratories
- Becton, Dickinson, and Company
- Biomerieux SA
- Bruker Corporation
- Charles River Laboratories International, Inc.
- Danaher Corporation
- Don Whitley Scientific Limited
- Merck KGaA
- Mocon, Inc
- Neogen Corporation
- Quidel Corporation
- Rapid Micro Biosystems Inc.
- Sartorius AG
- Thermo Fisher Scientific Inc.
- Vivione Biosciences LLC
- Other Prominent Players
- Reagents and Kits
- Clinical Disease Diagnosis
- Food & Beverage Testing
- Pharmaceutical & Biological Drug Testing
- Environmental Testing
- Cosmetics & Personal Care Products Testing
- Research Applications
- Laboratories & Hospitals
- Food & Beverage Companies
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- North America
- The U.S.
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Asia Pacific
- Australia & New Zealand
- South Korea
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Rest of South America
Directly Purchase a copy of report with TOC @ https://www.astuteanalytica.com/inquire-before-purchase/rapid-microbiology-testing-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)